Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-mwx4w Total loading time: 0 Render date: 2024-06-25T05:37:13.091Z Has data issue: false hasContentIssue false

E - Research in Gynaecological Oncology

Published online by Cambridge University Press:  04 August 2017

By
Sandra Soo-Hoo ,
Sudha Sundar  and
Sean T. Kehoe
Edited by
P. M. Shaughn O'Brien  and
Fiona Broughton Pipkin
P. M. Shaughn O'Brien
Affiliation:
Keele University School of Medicine
Fiona Broughton Pipkin
Affiliation:
University of Nottingham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Introduction to Research Methodology for Specialists and Trainees , pp. 255 - 259
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Mukhopadhyay, A, Plummer, ER, Elattar, A, et al. Clinicopathological features of homologous recombination–deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival. Cancer Research 2012;72(22):5675–82.CrossRefGoogle ScholarPubMed
Powell, MA, Sill, MW, Goodfellow, PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecologic Oncology 2014;135(1):38–43.CrossRefGoogle ScholarPubMed
Wiggans, AJ, Cass, GKS, Bryant, A, et al. Poly (ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. The Cochrane Library. Cochrane Database Syst Rev. 2015 May 20;(5):CD007929. doi:0.1002/14651858.CD007929.pub3Google Scholar
Li, J, Zhou, L, Chen, X, et al. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: A systematic review and meta-analysis of randomized trials. Clinical and Translational Oncology 2015:17(9) 673–83.CrossRefGoogle ScholarPubMed
Jacobs, IJ, Menon, U, Ryan, A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomized Controlled Trial. Obstetrical & Gynecological Survey 2016;71(6):346–8.CrossRefGoogle Scholar
Poole, EM, Rice, MS, Crum, CP et al. Salpingectomy as a potential ovarian cancer risk-reducing procedure. Journal of the National Cancer Institute 2015;107(2):dju490.CrossRefGoogle ScholarPubMed
Kehoe, S, Hook, J, Nankivell, M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. The Lancet 2015;386(9990):249–57.Google Scholar
Leslie, KK, Sill, MW, Fischer, E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: A Gynecologic Oncology Group study. Gynecologic Oncology 2013;129(3):486–94.Google Scholar
Covens, AL, Filiaci, V, Gersell, D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group study. Gynecologic Oncology 2011;120(2):185–8.Google Scholar
Joura, EA, Giuliano, AR, Iversen, O-E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. New England Journal of Medicine 2015;372(8):711–23.CrossRefGoogle ScholarPubMed
Eiriksson, LR, Covens, A. Sentinel lymph node mapping in cervical cancer: the future? BJOG: An International Journal of Obstetrics & Gynaecology 2012;119(2):129–33.CrossRefGoogle ScholarPubMed
Monk, BJ, Lopez, LM, Zarba, JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. Journal of Clinical Oncology 2010;28(22):3562–9.Google Scholar
Tewari, KS, Sill, MW, Long, HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. New England Journal of Medicine 2014;370(8):734–43.Google Scholar
te Grootenhuis, NC, van der Zee, AGJ, Van Doorn, HC, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecologic Oncology 2016;140(1):8–14.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×